Years in Business
What We Do
Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response to challenge. We give our partners access to every relevant antibody to meet their project goals.
Who We Are
Abterra Biosciences began life as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna are professors in the Computer Science and Engineering Department and leading researchers in bioinformatics. Their expertise forms the algorithmic foundation upon which our products and services are built. Read more about our unique solutions and recent product news.
Over the Years
Dr Pavel Pevzner
Ronald R. Taylor Professor of Computer Science and Engineering, UCSD
Director of the NIH Center for Computational Mass Spectrometry, UCSD
Dr Vineet Bafna
Professor of Computer Science and Engineering, UCSD
Founding Faculty of Halicioglou Data Science Institute, UCSD
Valens enables antibody sequencing and characterization direct from the protein.
Quorum uses mass spectrometry signatures to identify related molecules including metabolites, glycans, and peptides.
Alicanto extends the Valens technology to characterize diverse collections of antibodies derived from a natural immune response.
Reptor is a flexible, next-generation sequencing powered platform for B-cell receptor sequencing.
Abterra Biosciences was born and continues to deliver innovative antibody sequencing and discovery solutions to our partners.